Growing companies seeking to raise up to $50 million have a new financing option, starting Friday: a process that will open some private businesses to a wide pool of new investors.
More than three years in the making, the regulatory change, an expanded version of a rule known as Regulation A, is intended to let promising companies — the kinds typically backed by venture capitalists and wealthy angel investors — raise money by selling equity stakes to people of more modest means.
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today launched new Investigator® STR assay kits for analysis of DNA evidence in forensic laboratories in the United States. The new genetic fingerprint kits provide an integrated solution to simultaneously analyze multiple key genomic markers (short tandem repeats or STRs) for DNA matching. They incorporate the Investigator® Quality Sensor to evaluate the quality of DNA in each sample, a novel QIAGEN technology that enables labs to decide quickly which evidence may provide valuable results – solving cases while saving time and money.
The University of Maryland, Baltimore, will build a new interdisciplinary education facility thanks in part to a gift from a Baltimore construction company.
The university announced Wednesday that it’s getting $3 million from the Whiting-Turner Contracting Company. The money will go toward renovating a vacant building on the university campus in downtown Baltimore. When the work is finished, it will be home to the university’s Interprofessional Education Center.
One of the exciting and frustrating things about convergence, particularly in healthcare, is that it’s tough to predict how the hybrid technologies will find their way to market. The process of reaching that goal is filled with unexpected obstacles, twists and pivots.
United Therapeutics Corp., one of the region’s largest bioscience firms, is planning a major expansion of its Silver Spring campus with plans to hire about 100 employees in the next three to six years.
The publicly traded firm, with about 200 D.C.-area employees and $340 million in net income in 2014, wants to develop a six-story building at the southwest corner of Spring Street and Colesville Road connecting to its existing corporate presence in the immediate area. The 121,724-square-foot building, to include new office, lab and retail space, would be developed on the site of what is now a Montgomery County-owned, three-story parking garage that is under contract for sale to United Therapeutics (NASDAQ: UTHR).
German pharma giant Bayer is uniting with researchers at Johns Hopkins University to ferret out new treatments for retinal diseases, signing a 5-year deal targeting early-stage R&D.
Under the agreement, Bayer will work alongside the school’s Wilmer Eye Institute to spot new therapeutic targets, shed light on disease mechanisms and develop new drug delivery methods for back-of-the-eye ailments. Bayer will have exclusive rights to option any and all drug candidates that emerge from the collaboration, and the companies are keeping quiet on financial details.
Bayer HealthCare and Johns Hopkins University entered into a five-year collaboration to develop ophthalmic therapies that target retinal diseases. They will work together on discovery and development of drugs for treatment of eye diseases such as age-related macular degeneration and diabetic macular edema, among others.
72% percent of health IT leaders think consumer and patient considerations are the most important business issue affecting care delivery.
Registrants can now save $300 on MedCity ENGAGE on July 14-15 in Bethesda, MD. Sign up now to take advantage of advanced general registration.
MedCity ENGAGE is an executive-level event featuring the most innovative thinking from payers, providers, policymakers, health IT and beyond to highlight best-in-class approaches to one of the biggest challenges in healthcare: patient engagement. It will feature speakers discussing the current attempts to innovate in care delivery and reimbursement, along with the innovations that will form the backbone of technological infrastructure.
BioBuzz is an ongoing monthly networking group of professionals from all sectors of the Biotech/Pharma/Life-sciences industries. Each month we host a FREE event for like-minded people to come together and network, reconnect with past coworkers, build stronger relationships and share stimulating conversations in a welcoming atmosphere.
This month’s event is made possible by our sponsor, Breezio (@brzio), who is helping to advance the pace of research and discovery through their Research Collaboration Platform. Join us at the upcoming Bethesda event – June 25th at Barking Dog Bar – to meet them and learn about Team Science.
Lake Whillans, in an effort to help level the playing field for entrepreneurs in the new world of healthcare investing, has partnered with MedCity News to deliver independent research on corporate venture capital in the life sciences. MedCityNews.com reached out to its 400,000 monthly readers, and more than 450 healthcare innovators familiar with corporate firms shared their insights.
